Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.32
AHRO's Cash to Debt is ranked higher than
54% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.19 vs. AHRO: 0.32 )
AHRO' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.32

F-Score: 1
Z-Score: -179.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -1145.36
AHRO's ROA (%) is ranked lower than
57% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. AHRO: -1145.36 )
AHRO' s 10-Year ROA (%) Range
Min: -3924.06   Max: 1027.23
Current: -1145.36

-3924.06
1027.23
ROC (Joel Greenblatt) (%) -99569.44
AHRO's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. AHRO: -99569.44 )
AHRO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -90175   Max: -7250
Current: -99569.44

-90175
-7250
EBITDA Growth (%) -35.70
AHRO's EBITDA Growth (%) is ranked higher than
51% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. AHRO: -35.70 )
AHRO' s 10-Year EBITDA Growth (%) Range
Min: -96.3   Max: 284.9
Current: -35.7

-96.3
284.9
EPS Growth (%) -34.40
AHRO's EPS Growth (%) is ranked higher than
55% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. AHRO: -34.40 )
AHRO' s 10-Year EPS Growth (%) Range
Min: -96.5   Max: 341.4
Current: -34.4

-96.5
341.4
» AHRO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AHRO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -0.96
AHRO's EV-to-EBIT is ranked lower than
51% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.26 vs. AHRO: -0.96 )
AHRO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.96

Current Ratio 0.08
AHRO's Current Ratio is ranked lower than
56% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. AHRO: 0.08 )
AHRO' s 10-Year Current Ratio Range
Min: 0.01   Max: 4.31
Current: 0.08

0.01
4.31
Quick Ratio 0.08
AHRO's Quick Ratio is ranked lower than
56% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. AHRO: 0.08 )
AHRO' s 10-Year Quick Ratio Range
Min: 0.01   Max: 4.31
Current: 0.08

0.01
4.31

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -35.38
AHRO's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. AHRO: -35.38 )
AHRO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -35.38

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
AtheroNova, Inc. was incorporated in Delaware in 1997. The Company, through AtheroNova operations, engages in the development of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds principally for the treatment of atherosclerosis, which is the primary cause of cardiovascular diseases. As of December 31, 2012, it has not generated any revenues from the development of interllectual property and is therefore a development stage company.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK